Clinical Trials
4 trialsNCT01790126 2020-03-11
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 2 Completed
NCT00444639 2019-11-22
Study to Assess the Non-inferiority of PamorelinĀ® 11,25mg SC Injected Versus PamorelinĀ® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)
Ipsen
Phase 2 Terminated
NCT01374087 2019-09-18
ANABRAQ
Ipsen
Phase 2 Terminated
NCT01257425 2019-02-08
PAMIS
Ipsen
Phase 2 Completed